000			03108cam a2200421Ii 4500
999			_c96583 _d96583 _x1
001			96583
003			ES-MaUEC
005			20230102112801.0
006			m o d
007			cr cnu---unuuu
008			171011s2017 sz o 001 0 eng d
020			_a3319649582 _q(electronic bk.)
020			_a9783319649580 _q(electronic bk.)
020			_z3319649574
020			_z9783319649573
040			_aYDX _beng _erda _cYDX _dN$T _dEBLCP _dGW5XE _dN$T _dNOC _dCOD _dCOO _dMERER _dES-MaUEC _bspa
050		4	_aRC280.L5 _b2017 EB
245	0	0	_aImmunotherapy of hepatocellular carcinoma _cTim F. Greten, editor.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2017
300			_a1 recurso en línea (x, 267 páginas) _bilustraciones
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
500			_a
504			_aIncluye referencias bibliográficas e índice
505	0		_aPreface -- Introduction -- Vaccine approaches -- Spontaneous Immune responses to ablative therapies -- Antigen-specific T cell responses. Immune checkpoint inhibitors -- NASH and HCC -- Cytokine activated killer cells -- Sorafenib combination therapy -- Glypican 3 -- Suppressor cells -- Cytokines in HCC pathogenesis and treatment -- Index.
520	3		_a"Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical "inflammation-induced" cancer.
520	3		_aImmune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer, as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell-based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing significant benefit to a minority of patients.
520	3		_aIn this book we provide insights into liver - cancer and immunology. Experts in the field provide an overview of fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune-based approaches in HCC, which are gaining increasing interest in the community due to first promising results obtained in early clinical trials."--Preface.
588	0		_aOnline resource; title from PDF title page (EBSCO, viewed October 18, 2017)
988			_aEBOOK, EBSPRINGER_2017
650		7	_2embne _aHígado _xCáncer _9413204
650		7	_2embne _9139209 _aTumores
700	1		_aGreten, Tim F.
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-64958-0
942			_2lcc _cLE
998			_b02/2018 _dz _e- _zSI